RMOCX
Price
$15.26
Change
-$0.05 (-0.33%)
Updated
Sep 20 closing price
RRMGX
Price
$97.44
Change
-$0.69 (-0.70%)
Updated
Sep 20 closing price
Ad is loading...

RMOCX vs RRMGX

Header iconRMOCX vs RRMGX Comparison
Open Charts RMOCX vs RRMGXBanner chart's image
Victory RS Mid Cap Growth C
Price$15.26
Change-$0.05 (-0.33%)
VolumeN/A
CapitalizationN/A
T. Rowe Price Mid-Cap Growth R
Price$97.44
Change-$0.69 (-0.70%)
VolumeN/A
CapitalizationN/A
View a ticker or compare two or three
RMOCX vs RRMGX Comparison Chart
Loading...
VS
RMOCX vs. RRMGX commentary
Sep 21, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RMOCX is a Buy and RRMGX is a StrongBuy.

FUNDAMENTALS
Fundamentals
RRMGX has more cash in the bank: 31.4B vs. RMOCX (73.1M). RMOCX (0.00) and RRMGX (0.00) have matching dividends . RMOCX was incepted earlier than RRMGX: RMOCX (17 years) vs RRMGX (22 years). RMOCX is a more actively managed with annual turnover of: 119.00 vs. RRMGX (21.70). RMOCX (2500) and RRMGX (2500) have matching initial minimum investment requirements. RMOCX annual gain was more profitable for investors over the last year : 22.68 vs. RRMGX (13.62). RRMGX return over 5 years is better than : 9.23 vs. RMOCX (-29.48).
RMOCXRRMGXRMOCX / RRMGX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence17 years22 years-
Gain YTD10.4628.605122%
Front LoadN/AN/A-
Min. Initial Investment25002500100%
Min. Initial Investment IRAN/AN/A-
Net Assets73.1M31.4B0%
Annual Yield % from dividends0.000.00-
Returns for 1 year22.6813.62166%
Returns for 3 years-46.09-16.28283%
Returns for 5 years-29.489.23-320%
Returns for 10 years-12.8133.74-38%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OII26.020.16
+0.62%
Oceaneering International
COTY9.19-0.20
-2.13%
COTY
CLCO11.05-0.30
-2.64%
Cool Company Ltd
QLGN0.17-0.01
-3.55%
Qualigen Therapeutics
PRPH2.34-0.17
-6.77%
ProPhase Labs